Evidence map›Paper›PMID 22438314›Full record

ArticleCytometry. Part A : the journal of the International Society for Analytical Cytology2012

Cluster cytometry for high-capacity bioanalysis.

Bruce S Edwards, Jingshu Zhu, Jun Chen, Mark B Carter, David M Thal, John J G Tesmer, Steven W Graves, Larry A Sklar

Abstract read
In one paragraph

Article in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Flow Cytometry: Impact on Early Drug Discovery.Journal of biomolecular screening · 2015
    Review
  5. Article
  6. Review
  7. Article
  8. The role of HTS in drug discovery at the University of Michigan.Combinatorial chemistry & high throughput screening · 2014
    Review
  9. The University of New Mexico Center for Molecular Discovery.Combinatorial chemistry & high throughput screening · 2014
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Bruce S EdwardsDepartment of Pathology, University of New Mexico, Albuquerque, New Mexico, USA. bedwards@salud.unm.edu
Jingshu Zhu
Jun Chen
Mark B Carter
David M Thal
John J G Tesmer
Steven W Graves
Larry A Sklar

Funding

UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
Yeast Biology ConsortiumU54MH084690 · NIMH · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI TEGOS, GEORGE P · 2008 to 2013
$14.4M
University of New Mexico Clinical and Translational Science CenterUL1TR000041 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI LARSON, RICHARD S · 2012 to 2014
$9.8M
Structure, function, and inhibition of G protein-coupled receptor kinasesR01HL071818 · NHLBI · UNIVERSITY OF TEXAS AUSTIN · PI TESMER, JOHN · 2004 to 2023
$7.1M
Advancing High Throughput Flow CytometryR01HG005066 · NHGRI · UNIVERSITY OF NEW MEXICO · PI EDWARDS, BRUCE S · 2009 to 2010
$860k
RNA Aptamer-Based Screen for Selective Inhibitors of GRK2R03DA030557 · NIDA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TESMER, JOHN · 2010 to 2011
$76k
High-throughput multiplex microsphere screening for toxin protease inhibitorsR03MH093184 · NIMH · UNIVERSITY OF NEW MEXICO · PI GRAVES, STEVEN W · 2011 to 2012
$75k
NCATS NIH HHS UL1 TR000041NCATS NIH HHS UL1 TR001449NHGRI NIH HHS R01 HG005066NHGRI NIH HHS R01HG005066NHLBI NIH HHS R01 HL071818NIDA NIH HHS R03 DA030557NIDA NIH HHS R03 DA030557-01A1NIMH NIH HHS R03 MH093184NIMH NIH HHS R03MH093184-01A1NIMH NIH HHS U54 MH084690NIMH NIH HHS U54MH084690
6 · The paper itself

Abstract

Flow cytometry specializes in high-content measurements of cells and particles in suspension. Having long excelled in analytical throughput of single cells and particles, only recently with the advent of HyperCyt sampling technology, flow cytometry's multiexperiment throughput has begun to approach the point of practicality for efficiently analyzing hundreds-of-thousands of samples, the realm of high-throughput screening (HTS). To extend performance and automation compatibility, we built a HyperCyt-linked Cluster Cytometer platform, a network of flow cytometers for analyzing samples displayed in high-density, 1,536-well plate format. To assess the performance, we used cell- and microsphere-based HTS assays that had been well characterized in the previous studies. Experiments addressed important technical issues: challenges of small wells (assay volumes 10 μL or less, reagent mixing, cell and particle suspension), detecting and correcting for differences in performance of individual flow cytometers, and the ability to reanalyze a plate in the event of problems encountered during the primary analysis. Boosting sample throughput an additional fourfold, this platform is uniquely positioned to synergize with expanding suspension array and cell barcoding technologies in which as many as 100 experiments are performed in a single well or sample. As high-performance flow cytometers shrink in cost and size, cluster cytometry promises to become a practical, productive approach for HTS, and other large-scale investigations of biological complexity.

Indexed as

Equipment DesignFlow CytometryHigh-Throughput Screening AssaysSoftware

Identifiers

PMID22438314
PMCPMC3331957

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.